Skip to content Skip to footer
Subscribe Now
NEWS

Otsuka Pharmaceutical Reports P-III (VISIONARY) Trial Data on Voyxact for IgA Nephropathy (IgAN)

Shots: Otsuka reported the ongoing P-III (VISIONARY) trial data assessing Voyxact (sibeprenlimab; n= 320) vs PBO (n=152) in preserving kidney function in IgAN pts over a 24mos. treatment period At 12mos., Voyxactimproved kidney function with a mean eGFR change from baseline of +0.7 vs -4.8 mL/min/1.73 m², achieving the KDIGO treatment goal of limiting annual kidney…
June 5, 2026

Read more

Innovent
NEWS

Innovent Reports the P-III Trial Results on Arcotatug Tavatecan in G/GEJ Adenocarcinoma 

Shots: Innovent has reported the P-III (G-HOPE-001) of arcotatug tavatecan (IBI343/TAK-921) vs investigator-selected therapy in pts with Claudin 18.2 positive, locally advanced unresectable or metastatic G/GEJA who have received ≥2 prior therapies Trial met its 1EP of improved PFS in the interim analysis & showed a favorable safety profile; data to be published in future…
June 4, 2026

Read more

NEWS

Alvotech Reports the US FDA’s BLA Resubmission for AVT05 (Bisomilar, Simponi and Simponi Aria) and AVT06 (Biosimilar, Eylea)

Shots: The US FDA has received resubmitted BLA of AVT05, a biosimilar version of Simponi & Simponi Aria, and AVT06, a biosimilar to Eylea 2mg (aflibercept)  Resubmissions follow Alvotech’s response to the FDA’s PAAL regarding its Reykjavik facility, alongside responses to observations from a May 2026 routine cGMP inspection & ongoing enhancements to quality systems…
June 4, 2026

Read more

NEWS

Lundbeck Partners with Cradle to Accelerate AI-Driven Biotherapeutics Discovery

Shots: Lundbeck and Cradle entered a partnership to leverage AI-powered protein engineering for the discovery and optimization of biotherapeutics, with an initial focus on 2 antibody programs targeting CNS diseases Lundbeck will deploy Cradle’s generative AI platform in its first end-to-end AI-guided protein engineering workflow, using iterative feedback from experimental data to discover & optimize…
June 4, 2026

Read more

NEWS

CytomX and Regeneron Expand Tumor-Activated Bispecific Cancer Therapy Collaboration in Potential ~$4B Deal

Shots: CytomX has expanded its collaboration & licensing agreement with Regeneron to develop conditionally-activated bispecific cancer therapies using CytomX’s Probody platform & Regeneron’s Veloci-B BsAb development platform As per the expanded deal, the companies will continue joint discovery efforts to identify & validate conditionally active BsAbs, with Regeneron assuming responsibility for all preclinical & clinical development, commercialization,…
June 4, 2026

Read more

NEWS

Alnylam and Inceptive Enter ~$2B Collaboration to Accelerate AI-Powered Discovery of RNAi Therapeutics

Shots: Alnylam Pharmaceuticals & Inceptive Nucleics have entered into a strategic collaboration to accelerate the discovery of novel RNAi therapeutics The collaboration is valued at up to $2B, with $30M upfront, incl. cash & an equity investment in Inceptive. Inceptive will also receive additional preclinical, regulatory, & commercial milestone payments Collaboration combines Alnylam’s RNAi expertise…
June 4, 2026

Read more

NEWS

Ascidian and Eli Lilly Partner to Advance RNA Exon Editors for Devastating Kidney Diseases in a ~$1.9B Deal

Shots: Ascidian has entered a global research & licensing agreement with Eli Lilly to discover & develop therapies for undisclosed monogenic kidney diseases, with an option to expand the collaboration to additional targets As per the deal, Lilly will obtain exclusive target-specific rights to Ascidian’s RNA exon editing tech for undisclosed targets, with Ascidian leading…
June 3, 2026

Read more

Load more